PubMed Health⌕ Search

Biomedical subjects

J Sugars

Publications and source records attributed to J Sugars.

5 recordsLinked to original sources

Modification of catalytically active phospholipase D1 with fatty acid in vivo.

Phospholipase D1 (PLD1) was covalently labeled with 3H when expressed transiently in COS cells and immunoprecipitated following labeling of the cells with [3H]palmitate. Labeling of PLD1 was abolished by treatment with hydroxylamine at neutral pH, indicating that the fatty acid is linked via thioester to the enzyme. In pulse-chase studies the label persisted over a 3-h chase, indicating a slow rate of turnover. A catalytically inactive point mutant of PLD1 that changes serine at position 911 to alanine (S911A) was partially but not entirely redistributed to the cytosol, and it contained no detectable palmitate label. Similarly, N- and C-terminal domain fragments of the protein, encompassing in combination the entire coding region and all expressed to levels comparable with the wild type protein, showed no label with palmitate. Treatment of immunoprecipitated PLD1 with hydroxylamine diminished catalytic activity to background levels in a dose response manner that paralleled the removal of label from [3H]palmitate-labeled protein. We suggest that modification of PLD1 with palmitate is related to its catalytic activity and may be an important requirement for the function of this enzyme.

Amino Acid Sequence↗

A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia.

An 18-week, double-blind, crossover study of amantadine and neuroleptics in the treatment of tardive dyskinesia (TD) is described. A fixed-dose regimen was used, and objective rating scales for TD, extrapyramidal symptoms, and mental state were employed. The results indicate that amantadine is significantly better than placebo in the management of TD and that there is little risk of exacerbating psychosis. Further investigation of this potentially useful medication is warranted.

Aged↗

Decreased A23187-induced chemiluminescence in Duchenne muscular dystrophy granulocytes.

A number of recent reports suggest that intracellular calcium concentration is increased in skeletal muscle in duchenne muscular dystrophy (DMD). Leucocyte chemiluminescent responses are dependent on calcium ions and can be induced by the calcium ionophore A23187. Chemiluminescence may therefore reflect intracellular calcium levels. In order to determine whether non-muscle cells in DMD share the calcium abnormality, we have examined A23187-induced chemiluminescence in DMD leucocytes. Peak calcium dependent chemiluminescence occurred at 0.25-0.75 mM added calcium chloride. Peak chemiluminescent responses in the 13-paired samples were reduced in DMD leucocytes (P less than 0.01) using a paired t-test. These result suggest that there is an abnormality of calcium dependent A23187-induced chemiluminescence in DMD leucocytes and that there may be a generalised abnormality of calcium metabolism in DMD.

Anti-Bacterial Agents↗

An evaluation of lymphocyte capping in Duchenne muscular dystrophy.

There have been conflicting reports of lymphocyte capping abnormalities in Duchenne muscular dystrophy (DMD). We have evaluated the original method described by Verrill et al. in a "blind" study of 24 Duchenne muscular dystrophy boys and paired age-matched control boys. We found no differences in capping between the two groups but control boys had decreased capping compared to a group of normal adult males and females. It is concluded that the initial reports of decreased capping in DMD may have been due to differences in age between the test and control group.

Adult↗